Source comparison
TB-500 vs BPC-157 vs Standard Recovery Protocols
TB-500 Actin sequestration, VEGF upregulation, promotes cell migration to injury sites Preclinical (animal models); no RCTs in human athletes Prohibited 2–10mg/week subcutaneous or intramuscular, split doses Strongest angiogenesis signal; highest regulatory ri
This comparison does not assign a generated winner or score.
- TB-500
- Actin sequestration, VEGF upregulation, promotes cell migration to injury sites
- Preclinical (animal models); no RCTs in human athletes
- Prohibited
- 2–10mg/week subcutaneous or intramuscular, split doses
- Strongest angiogenesis signal; highest regulatory risk; limited human data
- BPC-157
- Promotes VEGF, stabilizes gastric mucosa, modulates nitric oxide pathways
- Preclinical (rodent studies); no human clinical trials published
- Not explicitly listed (regulatory gray area)
- 250–500mcg/day subcutaneous, near injury site
- More accessible; overlapping mechanism with TB-500; still lacks human trials
- NSAIDs + Physical Therapy
- COX enzyme inhibition (inflammation control); mechanical loading (collagen remodeling)
- Extensive RCT evidence in human populations
- Permitted (within dosing guidelines)
- Ibuprofen 400–800mg q6–8h; PT 2–3x/week for 6–12 weeks
- Gold standard with known risk profile; slower but evidence-backed
- Platelet-Rich Plasma (PRP)
- Autologous growth factor delivery (PDGF, TGF-β, IGF-1) to injury site
- Mixed evidence; some RCTs show benefit in tendinopathy; others show no effect
- Permitted (autologous)
- Single injection or series of 2–3 injections at injury site
- Variable efficacy; permitted in competition; costly